Company news

Hikma Pharmaceuticals PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Holding(s) in Company

October 21, 2026

Holding(s) in Company

October 20, 2026

Hikma appoints Rebecca Hall as CFO

September 24, 2026

Hikma R&D Investor Spotlight Series

September 22, 2026

Hikma Pharmaceuticals advances its epinephrine nasal spray with multi-market regulatory filings

September 9, 2026

Hikma Pharmaceuticals advances climate progress with first solar energy agreement

August 11, 2026

Directorate change

August 6, 2026

Half-year Financial Report

August 6, 2026

Hikma Pharmaceuticals welcomes FDA approval of Guardant360® Liquid CDx

June 22, 2026

Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

June 4, 2026

Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million

June 1, 2026

Hikma Pharmaceuticals and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) C...

May 5, 2026

Hikma Pharmaceuticals announces settlement agreement for VYNDAMAX® (tafamidis)

April 28, 2026

Hikma Pharmaceuticals reiterates full year 2026 guidance following encouraging start to the year

April 23, 2026

Transaction in Own Shares

March 23, 2026

Annual Financial Report and Notice of AGM

March 18, 2026

Director/PDMR Shareholding

March 11, 2026

Total Voting Rights

March 2, 2026

Launch of Buyback Programme

February 26, 2026

Final Results, Share Buyback & Leadership Changes

February 26, 2026

Hikma Pharmaceuticals launches authorised generic of Nucynta® (tapentadol) in the US

February 25, 2026

Statement regarding Hikma Pharmaceuticals Plc

February 4, 2026

Notice of Results

February 3, 2026

Par Health Names Dr. William Larkins as EVP and Chief Scientific Officer and President, Sterile Injectables

January 12, 2026

Hikma announces CEO change and Board appointment

December 15, 2025

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

December 8, 2025

Holding(s) in Company

November 11, 2025

November Trading Statement

November 6, 2025

Block listing Interim Review

October 1, 2025

Half-year Report

August 7, 2025

Publication of Offering Circular

July 7, 2025

Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US

July 2, 2025

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

June 28, 2025

Fitch upgrades Hikma to ‘BBB’

May 29, 2025

Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

May 27, 2025

Medium-term Group guidance ahead of US site visit

May 15, 2025

S&P upgrades Hikma to ‘BBB’

May 8, 2025

Settlement agreement for Xyrem® US lawsuits

May 8, 2025

Result of AGM

April 24, 2025

Trading Statement

April 24, 2025

Hikma acquires Novugen's FDA-approved ANDA for trametinib

April 17, 2025

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

March 20, 2025

Final Results

February 26, 2025

Outcome of Audit Tender Process

November 7, 2024

2024 Annual General Meeting Update Statement

October 24, 2024

Hikma completes Xellia acquisition

September 10, 2024

Director Declaration

July 29, 2024

Hikma acquires Xellia’s assets

June 17, 2024

Hikma appoints new President of Generics business

April 15, 2024

Agreement in Principle for US Opioid Settlement

February 1, 2024

Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 49 decks. Every deck is listed under its year.